Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Metoprolol Clear all
Terminated Phase 2Phase 3 Interventional

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

NCT00675714
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program
Procedure · Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 4, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Results available

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

NCT01970501
View directory record Official record
Conditions
Current or Recent History of Atrial Fibrillation
Interventions
bucindolol hydrochloride, metoprolol succinate, Placebo oral capsule
Drug · Other
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
48
States / cities
Anchorage, Alaska • Phoenix, Arizona • East Palo Alto, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 4, 2026, 8:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Nebivolol and the Endothelin (ET)-1 System

NCT01395329
View directory record Official record
Conditions
Prehypertension, Hypertension
Interventions
Nebivolol, Metoprolol, Placebo, Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min), FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min), FBF response to Acetylcholine, FBF response to Sodium Nitroprusside, FBF response to BQ-123+BQ-788+ACh
Drug · Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
45 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 1, 2019 · Synced Sep 4, 2026, 8:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)

NCT01595516
View directory record Official record
Conditions
Prehypertension, Hypertension
Interventions
Nebivolol, Metoprolol, Placebo, Bradykinin, Saline, Vitamin C
Drug · Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
45 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 4, 2026, 8:04 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

NCT05767346
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
28
States / cities
Anchorage, Alaska • Phoenix, Arizona • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 4, 2026, 8:04 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Aging, Beta Blockers, and Thermoregulatory Responses

NCT06582680
View directory record Official record
Conditions
Heat Stress, Aging
Interventions
Ambient Heat
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
65 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 4, 2026, 8:04 PM EDT
Completed Not applicable Interventional Results available

Nebivolol in the Supine Hypertension of Autonomic Failure

NCT01044693
View directory record Official record
Conditions
Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions
Placebo, Nebivolol 5 mg, metoprolol tartrate 50 mg, Sildenafil25 mg
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Sep 4, 2026, 8:04 PM EDT
Completed Phase 3 Interventional Results available

HALT Progression of Polycystic Kidney Disease Study A

NCT00283686
View directory record Official record
Conditions
Kidney, Polycystic
Interventions
Lisinopril, Telmisartan, Placebo, Standard Blood Pressure Control, Low Blood Pressure Control
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years to 64 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 4, 2026, 8:04 PM EDT
Completed Not applicable Interventional Results available

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

NCT01117454
View directory record Official record
Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
Flecainide Acetate, Placebo, Beta blocker
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
5 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 4, 2026, 8:04 PM EDT
Enrolling by invitation Phase 4 Interventional

Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)

NCT07298993
View directory record Official record
Conditions
Heart Failure, HFpEF, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Placebo (matching), Beta-blockers
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 4, 2026, 8:04 PM EDT
Terminated Phase 2Phase 3 Interventional

Propranolol in Severely Burned Children

NCT01957449
View directory record Official record
Conditions
Burn
Interventions
Propranolol, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 18 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
4
States / cities
Sacramento, California • Boston, Massachusetts • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 4, 2026, 8:04 PM EDT
Withdrawn Phase 2 Interventional

Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)

NCT05147415
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Placebo, Tesomet
Other · Drug
Lead sponsor
Saniona
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 4, 2026, 8:04 PM EDT
Completed Not applicable Interventional Results available

A Comparison of the Effects of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement

NCT00756236
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Metoprolol, Esmolol, P-Group
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 4, 2026, 8:04 PM EDT
Completed Phase 3 Interventional

Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects

NCT00255528
View directory record Official record
Conditions
Hypertension
Interventions
metoprolol succinate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 16 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
30
States / cities
Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2007 · Synced Sep 4, 2026, 8:04 PM EDT
Terminated Phase 3 Interventional

Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure

NCT00077948
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Enoximone, Metoprolol succinate, Placebo to match enoximone, Placebo to match metoprolol succinate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Denver, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Sep 4, 2026, 8:04 PM EDT
Terminated Phase 2 Interventional Results available

A Weight Loss Study in Overweight Men and Women

NCT00993421
View directory record Official record
Conditions
Obesity
Interventions
LY377604, Sibutramine, Metoprolol, Placebo sibutramine, Placebo Metoprolol, Placebo LY377604
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Mesa, Arizona • Concord, California • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2011 · Synced Sep 4, 2026, 8:04 PM EDT
Completed Phase 4 Interventional Results available

Nebivolol Versus Metoprolol: Sodium Sensitivity

NCT00992056
View directory record Official record
Conditions
Hypertension
Interventions
nebivolol, Metoprolol
Drug
Lead sponsor
University of Miami
Other
Eligibility
46 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 4, 2026, 8:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of LY2189265 on Two Blood Pressure Drugs

NCT01324388
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Metoprolol, Lisinopril, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Honolulu, Hawaii • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Sep 4, 2026, 8:04 PM EDT
Recruiting Not applicable Interventional

UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF

NCT07054489
View directory record Official record
Conditions
Heart Failure, Polygenic Score
Interventions
Beta blocker
Other
Lead sponsor
David Lanfear
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 4, 2026, 8:04 PM EDT
Completed Phase 1 Interventional

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
View directory record Official record
Conditions
Hypertension
Interventions
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
Drug · Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 4, 2026, 8:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome

NCT00775671
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
placebo, Nebivolol, Metoprolol
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Sep 4, 2026, 8:04 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 4, 2026, 8:04 PM EDT
Completed Phase 3 Interventional

Reversal of Ventricular Remodeling With Toprol-XL

NCT00038077
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Seloken ZOK/Toprol-XL, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
44
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Sep 4, 2026, 8:04 PM EDT
Completed Phase 3 Interventional Results available

Metoprolol to Reduce Perioperative Myocardial Injury

NCT03138603
View directory record Official record
Conditions
Heart Diseases
Interventions
Metoprolol Tartrate, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
50 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 4, 2026, 8:04 PM EDT